All News

Found 809 articles

• TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer

  7/6/2023

  TellBio, Inc., a development stage biotechnology company focused on revolutionizing detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx System, announces two publications that demonstrate the utility of CTC molecular analyses in patients with prostate cancer or advanced breast cancer.

• INOVIQ and Promega Announce Global Joint Marketing Agreement for EXO-NET Exosome Isolation and Nucleic Acid Purification Solutions

  7/6/2023

  INOVIQ and Promega sign a global joint marketing agreement for INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purification systems.

• Telo Genomics Announces Agreement for Strategic Advisory Services

  6/30/2023

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") announces that it has entered into an agreement with Leede Jones Gable Inc.

• Ribbon Biolabs Appoints Roopom Banerjee as Executive Chairman

  6/29/2023

  Ribbon Biolabs, the DNA synthesis company, announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors.

• Telo Genomics Presents Positive Data in Newly Diagnosed Multiple Myeloma Drug Resistance Study at EHA 2023

  6/28/2023

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") presented the results of its latest study on Friday June 09, 2023 at the European Hematology Association (EHA) 2023 annual meeting.

• Telo Genomics Completes Oversubscribed Private Placement

  6/14/2023

  Toronto, Ontario--(Newsfile Corp. - June 14, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") announces that it has closed its previously announced non-brokered private placement ("Offering") of units (the "Units").

• Genomill and Finland's Cancer Research Flagship iCAN Partner To Improve Cancer Detection Using an Extensive Biobank Cohort

  6/13/2023

  Genomill and iCAN, the Finnish national cancer research flagship project, signed a partnership aiming to improve the detection of trace tumour DNA from thousands of biobank samples.

•  U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib)

  6/9/2023

  U.S. Food and Drug Administration (FDA) Approves FoundationOne ® Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer.

• Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors

  6/6/2023

  Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors.

• Telo Genomics Announces Private Placement Increased to $2,766,375 from Previously Announced Private Placement of $2,000,000

  6/6/2023

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has increased the size of its previously announced non-brokered private placement ("Offering") from up to $2 million in proceeds to $2,766,375 and 11,065,500 units (the "Units" or each a "Unit").

• NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

  6/5/2023

  NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

• Telo Genomics Presents Superior Results of Its Smoldering Multiple Myeloma Studies at ASCO 2023

  6/5/2023

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is excited to announce that the results of its smoldering multiple myeloma (SMM) studies that were conducted in collaboration with the Mayo Clinic were presented earlier today at the American Society of Clinical Oncology (ASCO) 2023 annual meeting.

• Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing

  5/30/2023

  Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling (CGP) for oncology patients, which will be presented at the American Society of Clinical Oncology's Annual Meeting June 2–6 in Chicago.

• Liver Cancer Diagnostics Market Worth $15.95Bn, Globally, by 2028 at 8% CAGR - Exclusive Report by The Insight Partners

  5/30/2023

  The Insight Partners published latest research study on “Liver Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Laboratory Tests, Endoscopy, Imaging, Biopsy, and Others)

• Foundation Medicine and Its Collaborators Announce Acceptance of 21 Abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/26/2023

  Foundation Medicine, Inc., announced that the company and its collaborators will present 21 abstracts demonstrating the value of high-quality tumor profiling tests to inform cancer care at the 2023 American Society of Clinical Oncology Annual Meeting from June 2-6 in Chicago.

• Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer

  5/22/2023

  TellBio, Inc. announces publication of data that show the utility of CTCs isolated with TellDx to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a cohort of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who progress on endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibition.

• Telo Genomics Announces Private Placement of Units

  5/19/2023

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.25 per Unit for gross proceeds of $2,000,000 (the "Offering").

• Mercy BioAnalytics Appoints Diagnostics Industry Trailblazer Dr. Myla Lai-Goldman to Its Board of Directors

  4/24/2023

  Mercy BioAnalytics, Inc. today announced the appointment of Myla Lai-Goldman, MD, to its Board of Directors.

• Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer

  4/20/2023

  Immunovia announced it will participate in a webinar titled "Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer" hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET.

• Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel

  4/19/2023

  Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program for molecular diagnostic tests performed in our region.